Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma
| Autor: | Ke-Feng Wang, Xiaoqin Chen, Bo-Yang Chang, Zhongjun Xia, Liang Wang |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Epidemiology Injections Subcutaneous Urology Once weekly Drug Administration Schedule law.invention Bortezomib Subcutaneous injection Randomized controlled trial law medicine Humans In patient Multiple myeloma Aged business.industry Public Health Environmental and Occupational Health medicine.disease Surgery Peripheral neuropathy Oncology Cohort Injections Intravenous Female business Multiple Myeloma medicine.drug |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP. 16(5) |
| ISSN: | 2476-762X |
| Popis: | In patients with multiple myeloma (MM), once-weekly intravenous injection or twice-weekly subcutaneous injection (SC) of bortezomib has been proven to offer non-inferior efficacy to standard twice-weekly intravenous administration, with an improved safety profile. However, whether once-weekly SC bortezomib can further reduce the incidence rate of peripheral neuropathy (PN) and not compromise the efficacy remains to be investigated. 25 patients of MM treated with once-weekly SC bortezomib were reviewed in this study. The median treatment cycles were 4 (range, 2-9 cycles). Complete response (CR) rate was 52%, ≥very good partial response (VGPR) rate was 72%, and ≥partial response (PR) rate was 84%. 1-year and 2-year PFS rate was 63.0% and 34.3%, respectively, and 2-year OS rate was 100%. Any grade of PN was reported in 9 patients (36.0%), with 7 patients (28.0%) had grade 1 PN, and 2 patients (8.0%) had grade 2 PN. No patients reported grade 3/4 PN in this cohort. In conclusion, once-weekly subcutaneous administration of bortezomib offers excellent efficacy with a further improved safety profile, especially with regard to PN. It needs to be validated in future prospective randomized trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|